Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vemurafenib in Poor Performance Status Melanoma
NCT01474551Phase 2Terminated
- Sponsor
- Memorial Sloan Kettering Cancer Center
- Start
- Nov 2011
- Primary completion
- Mar 2013
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of vemurafenib in melanoma, sponsored by Memorial Sloan Kettering Cancer Center. Started Nov 2011; status: terminated.
02
Drugs
vemurafenib
03
Conditions
melanoma
Beyond the preview
Go deeper on NCT01474551.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01474551.